title: Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy.
abstract: We investigated whether statin use is associated with reduced risk of recurrence in prostate cancer patients who undergo radiotherapy. A retrospective cohort of 774 patients from a California health plan was followed for 5 years. Statin use prior to, during and after radiotherapy was not associated with prostate cancer recurrence [hazard ratio=0.99 (0.70-1.39), 0.87 (0.62-1.22) and 0.78 (0.55-1.09), respectively] in multivariable Cox models. No clear dose-response relationship was observed for average daily statin dose or duration of statin use. Our findings do not support a preventive benefit of statins in prostate cancer recurrence after radiotherapy.
authors: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA. chun.r.chao@kp.org
authors: Chun
authors: C
authors: Chao
authors: Stephen G
authors: SG
authors: Williams
authors: Lanfang
authors: L
authors: Xu
authors: Jergin
authors: J
authors: Chen
authors: Lauren P
authors: LP
authors: Wallner
authors: Kimberly R
authors: KR
authors: Porter
authors: Steven J
authors: SJ
authors: Jacobsen
mesh_terms: D000368:Aged; D015331:Cohort Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced* / Q000517:prevention & control; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000401:mortality / Q000532:radiotherapy; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors